Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone832-384-1100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.12 million
Profitability
Miscellaneous
Employees173
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) posted its quarterly earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.04. The biopharmaceutical company earned $1.39 million during the quarter, compared to analysts' expectations of $0.23 million. Bellicum Pharmaceuticals had a negative return on equity of 169.33% and a negative net margin of 4,081.44%. View Bellicum Pharmaceuticals' Earnings History.
When is Bellicum Pharmaceuticals' next earnings date?
Has Bellicum Pharmaceuticals been receiving favorable news coverage?
Media headlines about BLCM stock have been trending negative this week, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a news impact score of -2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Bellicum Pharmaceuticals.
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include AcelRx Pharmaceuticals (ACRX), Spero Therapeutics (SPRO), Imprimis Pharmaceuticals (IMMY), Constellation Pharmaceuticals (CNST), Adamas Pharmaceuticals (ADMS), Nature's Sunshine Products (NATR), TAIWAN LIPOSOME/S (TLC), Affimed (AFMD), LifeVantage (LFVN), Newron Pharmaceuticals (NWPHF), Poxel (PXXLF), Applied Therapeutics (APLT), American Brivision (Holding) (ABVC), Osmotica Pharmaceuticals (OSMT) and Sol Gel Technologies (SLGL).
What other stocks do shareholders of Bellicum Pharmaceuticals own?
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the folowing people:
- Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
- Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
- Mr. Thomas J. Farrell, Consultant (Age 56)
- Mr. Atabak Mokari, Chief Financial Officer (Age 42)
- Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller
When did Bellicum Pharmaceuticals IPO?
(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.
Who are Bellicum Pharmaceuticals' major shareholders?
Bellicum Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (7.31%), Sumitomo Mitsui Trust Holdings Inc. (4.55%), Nikko Asset Management Americas Inc. (4.55%), Vanguard Group Inc. (4.06%), Renaissance Technologies LLC (3.38%) and ARK Investment Management LLC (2.78%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker, David M Spencer and Jon P Stonehouse. View Institutional Ownership Trends for Bellicum Pharmaceuticals.
Which major investors are selling Bellicum Pharmaceuticals stock?
BLCM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Vanguard Group Inc., Bank of New York Mellon Corp, ARK Investment Management LLC, Charles Schwab Investment Management Inc., Wells Fargo & Company MN and Northern Trust Corp. View Insider Buying and Selling for Bellicum Pharmaceuticals.
Which major investors are buying Bellicum Pharmaceuticals stock?
BLCM stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Renaissance Technologies LLC, Jane Street Group LLC, Paloma Partners Management Co, GSA Capital Partners LLP, AXA and Algert Global LLC. View Insider Buying and Selling for Bellicum Pharmaceuticals.
How do I buy shares of Bellicum Pharmaceuticals?
Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellicum Pharmaceuticals' stock price today?
One share of BLCM stock can currently be purchased for approximately $0.93.
How big of a company is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals has a market capitalization of $43.02 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.View Additional Information About Bellicum Pharmaceuticals.
What is Bellicum Pharmaceuticals' official website?
How can I contact Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]
MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
